Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.verified

PTGX

Price:

$30.74

Market Cap:

$1.80B

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment ...[Read more]

Industry

Biotechnology

IPO Date

2016-08-11

Stock Exchange

NASDAQ

Ticker

PTGX

The PE Ratio as of May 2024 (TTM) for Protagonist Therapeutics, Inc. (PTGX) is 12.10

According to Protagonist Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 12.10. This represents a change of -1898.94% compared to the average of -0.67 of the last 4 quarters.

Protagonist Therapeutics, Inc. (PTGX) Historical PE Ratio (quarterly & annually)

How has PTGX PE Ratio performed in the past?

The mean historical PE Ratio of Protagonist Therapeutics, Inc. over the last ten years is -7.51. The current 12.10 PE Ratio has changed -16209.32% with respect to the historical average. Over the past ten years (40 quarters), PTGX's PE Ratio was at its highest in in the December 2023 quarter at 12.66. The PE Ratio was at its lowest in in the December 2017 quarter at -34.41.

Quarterly (TTM)
Annual

Average

-7.51

Median

-5.43

Minimum

-16.49

Maximum

-2.37

Protagonist Therapeutics, Inc. (PTGX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Protagonist Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 343.23%

Maximum Annual PE Ratio = -2.37

Minimum Annual Increase = -66.44%

Minimum Annual PE Ratio = -16.49

Quarterly (TTM)
Annual
YearPE RatioChange
2023-16.49280.24%
2022-4.34-66.44%
2021-12.9223.24%
2020-10.48343.23%
2019-2.37-38.84%
2018-3.87-61.17%
2017-9.96158.95%
2016-3.85-17.01%
2015-4.63-25.48%

Protagonist Therapeutics, Inc. (PTGX) Average PE Ratio

How has PTGX PE Ratio performed in the past?

The current PE Ratio of Protagonist Therapeutics, Inc. (PTGX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-11.25

5-year avg

-9.32

10-year avg

-7.51

Protagonist Therapeutics, Inc. (PTGX) PE Ratio vs. Peers

How is PTGX’s PE Ratio compared to its peers?

Protagonist Therapeutics, Inc.’s PE Ratio is greater than Revolution Medicines, Inc. (-13.41), greater than Akero Therapeutics, Inc. (-6.59), greater than Avidity Biosciences, Inc. (-11.25), greater than Stoke Therapeutics, Inc. (-5.92), greater than Kura Oncology, Inc. (-11.07), greater than Merus N.V. (-17.04), greater than Replimune Group, Inc. (-1.99), greater than Cerevel Therapeutics Holdings, Inc. (-16.60), greater than Relay Therapeutics, Inc. (-2.64), greater than Pliant Therapeutics, Inc. (-5.38), greater than Black Diamond Therapeutics, Inc. (-3.16), greater than Arvinas, Inc. (-6.60), greater than Ventyx Biosciences, Inc. (-1.52), greater than IDEAYA Biosciences, Inc. (-23.60), greater than Verona Pharma plc (-16.52), greater than Syndax Pharmaceuticals, Inc. (-7.19), greater than Terns Pharmaceuticals, Inc. (-4.82), greater than X4 Pharmaceuticals, Inc. (-1.44), greater than Acumen Pharmaceuticals, Inc. (-3.90), greater than Day One Biopharmaceuticals, Inc. (-6.71), greater than HOOKIPA Pharma Inc. (-2.15),

Build a custom stock screener for Protagonist Therapeutics, Inc. (PTGX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protagonist Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Protagonist Therapeutics, Inc. (PTGX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Protagonist Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Protagonist Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Protagonist Therapeutics, Inc. (PTGX)?

What is the highest PE Ratio for Protagonist Therapeutics, Inc. (PTGX)?

What is the 3-year average PE Ratio for Protagonist Therapeutics, Inc. (PTGX)?

What is the 5-year average PE Ratio for Protagonist Therapeutics, Inc. (PTGX)?

How does the current PE Ratio for Protagonist Therapeutics, Inc. (PTGX) compare to its historical average?